Use of CRF antagonists and renin-angiotensin system inhibitors
AssigneePfizer Inc.
InventorAnthony A. Fossa
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.
Claims26
A pharmaceutical composition which comprises amounts of a corticotropin releasing factor antagonist, a renin-angiotensin system inhibitor and a pharmaceutically acceptable carrier or diluent.
A kit which comprises an amount of a corticotropin releasing factor antagonist and a pharmaceutically acceptable carrier or diluent in a first unit dosage form, an amount of a renin-angiotensin system inhibitor and a pharmaceutically acceptable carrier or diluent in a second unit dosage form and a container.
A method of treating congestive heart failure or hypertension which method comprises administering to an animal in need of such treatment synergistic therapeutically effective amounts of a corticotropin releasing factor antagonist and a renin-angiotensin system inhibitor.
Dependencies are inferred from the claim text.